Gene Expression Profiling of Triple-Negative Breast Tumors with Different Expression of Secreted Protein Acidic And Cysteine Rich (SPARC)

References

• Ferlay J , Soerjomataram I , Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136(5), E359–E386 (2015).
   PubMed Web of Science ®Google Scholar
• Arvold ND , Taghian AG , Niemierko A et al. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J. Clin. Oncol. 29(29), 3885–3891 (2011).
   PubMed Web of Science ®Google Scholar
• Noh JM , Choi DH , Huh SJ et al. Patterns of recurrence after breast-conserving treatment for early Stage breast cancer by molecular subtype. J. Breast Cancer 14(1), 46–51 (2011).
   PubMed Web of Science ®Google Scholar
• Ahn SG , Kim SJ , Kim C , Jeong J . Molecular classification of triple-negative breast cancer. J. Breast Cancer 19(3), 223–230 (2016).
   PubMed Web of Science ®Google Scholar
• Partridge AH , Hughes ME , Warner ET et al. Subtype-dependent relationship between young age at diagnosis and breast cancer survival. J. Clin. Oncol. 34(27), 3308–3314 (2016).
   PubMed Web of Science ®Google Scholar
• Cossetti RJ , Tyldesley SK , Speers CH , Zheng Y , Gelmon KA . Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008. J. Clin. Oncol. 33(1), 65–73 (2015).
   PubMed Web of Science ®Google Scholar
• Engebraaten O , Vollan HK , B⊘rresen-Dale AL . Triple-negative breast cancer and the need for new therapeutic targets. Am. J. Pathol. 183(4), 1064–1074 (2013).
   PubMed Web of Science ®Google Scholar
• Foulkes WD , Smith IE , Reis-Filho JS . Triple-negative breast cancer. N. Engl. J. Med. 363(20), 1938–1948 (2010).
   PubMed Web of Science ®Google Scholar
• Boyle P . Triple-negative breast cancer: epidemiological considerations and recommendations. Ann. Oncol. 23(Suppl. 6), vi7–12 (2012).
   PubMed Web of Science ®Google Scholar
• Pareja F , Geyer FC , Marchiò C , Burke KA , Weigelt B , Reis-Filho JS . Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-Grade variants. NPJ Breast Cancer 2, 16036 (2016).
   PubMed Web of Science ®Google Scholar
• Carey LA , Perou CM , Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21), 2492–2502 (2006).
   PubMed Web of Science ®Google Scholar
• Kurebayashi J , Moriya T , Ishida T et al. The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast 16(Suppl. 2), S72–S77 (2007).
   PubMedGoogle Scholar
• Byrski T , Huzarski T , Dent R et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res. Treat. 115(2), 359–363 (2009).
   PubMed Web of Science ®Google Scholar
• Fostira F , Tsitlaidou M , Papadimitriou C et al. Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast Cancer Res. Treat. 134(1), 353–362 (2012).
   PubMed Web of Science ®Google Scholar
• Greenup R , Buchanan A , Lorizio W et al. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann. Surg. Oncol. 20(10), 3254–3258 (2013).
   PubMed Web of Science ®Google Scholar
• Herschkowitz JI , He X , Fan C , Perou CM . The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res. 10(5), R75 (2008).
   PubMed Web of Science ®Google Scholar
• Ding L , Ellis MJ , Li S et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464(7291), 999–1005 (2010).
   PubMed Web of Science ®Google Scholar
• Curtis C , Shah SP , Chin SF et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403), 346–352 (2012).
   PubMed Web of Science ®Google Scholar
• Hudis CA , Gianni L . Triple-negative breast cancer: an unmet medical need. Oncologist 16(Suppl. 1), 1–11 (2011).
   PubMed Web of Science ®Google Scholar
• Byrski T , Gronwald J , Huzarski T et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J. Clin. Oncol. 28(3), 375–379 (2010).
   PubMed Web of Science ®Google Scholar
• Colleoni M , Cole BF , Viale G et al. Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J. Clin. Oncol. 28(18), 2966–2973 (2010).
   PubMed Web of Science ®Google Scholar
• Silver DP , Richardson AL , Eklund AC et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J. Clin. Oncol. 28(7), 1145–1153 (2010).
   PubMed Web of Science ®Google Scholar
• Brekken RA , Sage EH . SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol. 19(8), 816–827 (2001).
   PubMedGoogle Scholar
• Framson PE , Sage EH . SPARC and tumor growth: where the seed meets the soil? J. Cell Biochem. 92(4), 679–690 (2004).
   PubMed Web of Science ®Google Scholar
• Bradshaw AD . Diverse biological functions of the SPARC family of proteins. Int. J. Biochem. Cell Biol. 44(3), 480–488 (2012).
   PubMed Web of Science ®Google Scholar
• Arnold SA , Brekken RA . SPARC: a matricellular regulator of tumorigenesis. J. Cell Commun. Signal 3(3–4), 255–273 (2009).
   PubMed Web of Science ®Google Scholar
• Porte H , Chastre E , Prevot S et al. Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. Int. J. Cancer 64(1), 70–75 (1995).
   PubMed Web of Science ®Google Scholar
• Brown TJ , Shaw PA , Karp X , Huynh MH , Begley H , Ringuette MJ . Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer. Gynecol. Oncol. 75(1), 25–33 (1999).
   PubMed Web of Science ®Google Scholar
• Wang CS , Lin KH , Chen SL , Chan YF , Hsueh S . Overexpression of SPARC gene in human gastric carcinoma and its clinic-pathologic significance. Br. J. Cancer 91(11), 1924–1930 (2004).
   PubMed Web of Science ®Google Scholar
• Chin D , Boyle GM , Williams RM et al. Novel markers for poor prognosis in head and neck cancer. Int. J. Cancer 113(5), 789–797 (2005).
   PubMed Web of Science ®Google Scholar
• Tai IT , Dai M , Owen DA , Chen LB . Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J. Clin. Invest. 115(6), 1492–1502 (2005).
   PubMed Web of Science ®Google Scholar
• Desai N , Trieu V , Damascelli B , Soon-Shiong P . SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl. Oncol. 2(2), 59–64 (2009).
   PubMed Web of Science ®Google Scholar
• Nagai MA , Gerhard R , Fregnani JH et al. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients. Breast Cancer Res. Treat. 126(1), 1–14 (2011).
   PubMed Web of Science ®Google Scholar
• Chomczynski P , Sacchi N . Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162(1), 156–159 (1987).
   PubMed Web of Science ®Google Scholar
• de Bessa Garcia SA , Pavanelli AC , Cruz E , Melo N , Nagai MA . Prostate apoptosis response 4 (PAR4) expression modulates WNT signaling pathways in MCF7 breast cancer cells: a possible mechanism underlying PAR4-mediated docetaxel chemosensitivity. Int. J. Mol. Med. 39(4), 809–818 (2017).
   PubMed Web of Science ®Google Scholar
• Edgar R , Domrachev M , Lash AE . Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30(1), 207–210 (2002).
   PubMed Web of Science ®Google Scholar
• De Bessa SA , Salaorni S , Patrão DF , Neto MM , Brentani MM , Nagai MA . JDP1 (DNAJC12/Hsp40) expression in breast cancer and its association with estrogen receptor status. Int. J. Mol. Med. 17(2), 363–367 (2006).
   PubMed Web of Science ®Google Scholar
• Szász AM , Lánczky A , Nagy Á et al. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget 7(31), 49322–49333 (2016).
   PubMedGoogle Scholar
• Rakha EA , Ellis IO . Triple-negative/basal-like breast cancer: review. Pathology 41(1), 40–47 (2009).
   PubMed Web of Science ®Google Scholar
• Ali AM , Ansari JAK , El-Aziz NMA et al. Triple negative breast cancer: a tale of two decades. Anticancer Agents Med. Chem. 17(4), 491–499 (2017).
   PubMed Web of Science ®Google Scholar
• Sun H , Ghaffari S , Taneja R . bHLH-orange transcription factors in development and cancer. Transl. Oncogenomics 2, 107–120 (2007).
   PubMedGoogle Scholar
• Ballow DJ , Xin Y , Choi Y , Pangas SA , Rajkovic A . SOHLH2 is a germ cell-specific bHLH transcription factor. Gene Expr. Patterns 6(8), 1014–1018 (2006).
   PubMed Web of Science ®Google Scholar
• Toyoda S , Miyazaki T , Miyazaki S et al. SOHLH2 affects differentiation of KIT positive oocytes and spermatogonia. Dev. Biol. 325(1), 238–248 (2009).
   PubMed Web of Science ®Google Scholar
• Suzuki H , Ahn HW , Chu T et al. SOHLH1 and SOHLH2 coordinate spermatogonial differentiation. Dev. Biol. 361(2), 301–312 (2012).
   PubMed Web of Science ®Google Scholar
• Lukk M , Kapushesky M , Nikkilä J et al. A global map of human gene expression. Nat. Biotechnol. 28(4), 322–324 (2010).
   PubMed Web of Science ®Google Scholar
• Zhang H , Zhang X , Ji S et al. Sohlh2 inhibits ovarian cancer cell proliferation by upregulation of p21 and downregulation of cyclin D1. Carcinogenesis 35(8), 1863–1871 (2014).
   PubMed Web of Science ®Google Scholar
• Ji S , Zhang W , Zhang X et al. Sohlh2 suppresses epithelial to mesenchymal transition in breast cancer via downregulation of IL-8. Oncotarget 7(31), 49411–49424 (2016).
   PubMedGoogle Scholar
• Lee J , Hahn Y , Yun JH , Mita K , Chung JH . Characterization of JDP genes, an evolutionarily conserved J domain-only protein family, from human and moths. Biochim. Biophys. Acta 1491(1–3), 355–363 (2000).
   PubMedGoogle Scholar
• Qiu XB , Shao YM , Miao S , Wang L . The diversity of the DnaJ/Hsp40 family, the crucial partners for Hsp70 chaperones. Cell. Mol. Life Sci. 63(22), 2560–2570 (2006).
   PubMed Web of Science ®Google Scholar
• Mitra A , Shevde LA , Samant RS . Multi-faceted role of HSP40 in cancer. Clin. Exp. Metastasis 26(6), 559–567 (2009).
   PubMed Web of Science ®Google Scholar
• Nagai MA , Da Rós N , Neto MM et al. Gene expression profiles in breast tumors regarding the presence or absence of estrogen and progesterone receptors. Int. J. Cancer 111(6), 892–899 (2004).
   PubMed Web of Science ®Google Scholar
• Choi J , Djebbar S , Fournier A , Labrie C . The co-chaperone DNAJC12 binds to Hsc70 and is upregulated by endoplasmic reticulum stress. Cell Stress Chaperones 19(3), 439–446 (2014).
   PubMed Web of Science ®Google Scholar
• He HL , Lee YE , Chen HP et al. Overexpression of DNAJC12 predicts poor response to neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer. Exp. Mol. Pathol. 98(3), 338–345 (2015).
   PubMed Web of Science ®Google Scholar
• Matthews JM , Lester K , Joseph S , Curtis DJ . LIM-domain-only proteins in cancer. Nat. Rev. Cancer 13(2), 111–122 (2013).
   PubMed Web of Science ®Google Scholar
• Sum EY , Segara D , Duscio B et al. Overexpression of LMO4 induces mammary hyperplasia, promotes cell invasion, and is a predictor of poor outcome in breast cancer. Proc. Natl Acad. Sci. USA 102(21), 7659–7664 (2005).
   PubMed Web of Science ®Google Scholar
• Bagheri-Yarmand R , Mazumdar A , Sahin AA , Kumar R . LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system. Int. J. Cancer 118(11), 2703–2710 (2006).
   PubMed Web of Science ®Google Scholar
• Yoshioka K , Foletta V , Bernard O , Itoh K . A role for LIM kinase in cancer invasion. Proc. Natl Acad. Sci. USA 100(12), 7247–7252 (2003).
   PubMed Web of Science ®Google Scholar
• Singh RR , Barnes CJ , Talukder AH , Fuqua SA , Kumar R . Negative regulation of estrogen receptor alpha transactivation functions by LIM domain only 4 protein. Cancer Res. 65(22), 10594–10601 (2005).
   PubMed Web of Science ®Google Scholar
• Montañez-Wiscovich ME , Seachrist DD , Landis MD , Visvader J , Andersen B , Keri RA . LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression. Oncogene 28(41), 3608–3618 (2009).
   PubMed Web of Science ®Google Scholar
• Weinstein JN , Collisson EA , Mills GB et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 45(10), 1113–1120 (2013).
   PubMed Web of Science ®Google Scholar
• Lane TF , Iruela-Arispe ML , Sage EH . Regulation of gene expression by SPARC during angiogenesis in vitro. Changes in fibronectin, thrombospondin-1, and plasminogen activator inhibitor-1. J. Biol. Chem. 267(23), 16736–16745 (1992).
   PubMed Web of Science ®Google Scholar
• Golembieski WA , Rempel SA . cDNA array analysis of SPARC-modulated changes in glioma gene expression. J. Neurooncol. 60(3), 213–226 (2002).
   PubMed Web of Science ®Google Scholar
• Fujita T , Shiba H , Sakata M , Uchida Y , Nakamura S , Kurihara H . SPARC stimulates the synthesis of OPG/OCIF, MMP-2 and DNA in human periodontal ligament cells. J. Oral Pathol. Med. 31(6), 345–352 (2002).
   PubMed Web of Science ®Google Scholar